{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:10:16Z","timestamp":1792894216152,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aims of this study were to investigate the impact of the relative dose intensity (RDI) of chemotherapy on disease-free survival (DFS) and overall survival (OS), to identify the optimal RDI cut-off points with the docetaxel, epirubicin and cyclophosphamide (TEC) regimen for stage I\u2013III breast cancer patients and to explore the adverse events in these patients. To achieve this, we performed a retrospective analysis of breast cancer patients treated at the First Affiliated Hospital of Chongqing Medical University in 2011. The results showed that among 293 patients with the TEC regimen, 85% and 80% were the cut-off points at which a high RDI was associated with better overall survival (HR = 2.04; 95% CI 1.13, 3.70; p = 0.02) and disease-free survival (HR = 1.97; 95% CI 1.14\u20133.42; p = 0.02), respectively. Among 169 HR(+) patients, 80% was the cut-off point for DFS (HR = 2.33; 95% CI 1.07\u20135.08; p = 0.03), and 85% was the cut-off point for OS (HR = 3.00; 95% CI 1.24\u20137.26; p = 0.02). Among 105 HR(\u2212) patients, 80% was the cut-off point for OS (HR = 2.86; 95% CI 1.05\u20137.80; p = 0.04). Of 293 patients, neutropenia, nausea, and vomiting were found to be correlated with the level of RDI. In conclusion, a higher RDI of chemotherapy is associated with better survival but with a higher probability of causing adverse events. To optimize survival benefits, the RDI should be maintained \u2265 85% for HR(+) patients and \u2265 80% for HR(\u2212) patients.<\/jats:p>","DOI":"10.1038\/s41598-020-70187-8","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T06:04:51Z","timestamp":1596693891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Wanwan","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"issue":"9132","key":"70187_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet352(9132), 930\u2013942 (1998).","journal-title":"Lancet"},{"issue":"6","key":"70187_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/jnci\/90.6.468","volume":"90","author":"CD Atkins","year":"1998","unstructured":"Atkins, C. D. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst.90(6), 468\u2013469. https:\/\/doi.org\/10.1093\/jnci\/90.6.468 (1998).","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"70187_CR3","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.1998.16.11.3486","volume":"16","author":"EG Mansour","year":"1998","unstructured":"Mansour, E. G. et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis\u2014An intergroup study. J. Clin. Oncol.16(11), 3486\u20133492. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3486 (1998).","journal-title":"J. Clin. Oncol."},{"issue":"9472","key":"70187_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet365(9472), 1687\u20131717. https:\/\/doi.org\/10.1016\/S0140-6736(05)66544-0 (2005).","journal-title":"Lancet"},{"issue":"6","key":"70187_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson, I. C. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol.21(6), 976\u2013983. https:\/\/doi.org\/10.1200\/JCO.2003.02.063 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"70187_CR6","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann, W. et al. Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J. Clin. Oncol.29(29), 3877\u20133884 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"70187_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/annonc\/mdw098","volume":"27","author":"JR Mackey","year":"2016","unstructured":"Mackey, J. R. et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann. Oncol.27(6), 1041\u20131047 (2016).","journal-title":"Ann. Oncol."},{"issue":"14","key":"70187_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199504063321401","volume":"332","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna, G. et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N. Engl. J. Med.332(14), 901\u2013906. https:\/\/doi.org\/10.1056\/NEJM199504063321401 (1995).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"70187_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman, D. R. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl. Cancer Inst.90(16), 1205\u20131211. https:\/\/doi.org\/10.1093\/jnci\/90.16.1205 (1998).","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"70187_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella, I. et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res. Treat.114(3), 479\u2013484. https:\/\/doi.org\/10.1007\/s10549-008-0018-1 (2009).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"70187_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","volume":"93","author":"LJ Havrilesky","year":"2015","unstructured":"Havrilesky, L. J. et al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit. Rev. Oncol. Hematol.93(3), 203\u2013210. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"70187_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.03.023","author":"N Fristrup","year":"2019","unstructured":"Fristrup, N. & Donskov, F. Folic acid reduces mucositis in metastatic renal cell carcinoma patients: A retrospective study. Clin. Genitourin. Cancer\nhttps:\/\/doi.org\/10.1016\/j.clgc.2019.03.023 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"issue":"8","key":"70187_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1200\/JCO.1986.4.8.1162","volume":"4","author":"W Hryniuk","year":"1986","unstructured":"Hryniuk, W. & Levine, M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol.4(8), 1162\u20131170. https:\/\/doi.org\/10.1200\/JCO.1986.4.8.1162 (1986).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"70187_CR14","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1200\/JCO.1991.9.11.2042","volume":"9","author":"DL Longo","year":"1991","unstructured":"Longo, D. L. et al. The calculation of actual or received dose intensity: A comparison of published methods. J. Clin. Oncol.9(11), 2042\u20132051. https:\/\/doi.org\/10.1200\/JCO.1991.9.11.2042 (1991).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"70187_CR15","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman, G. H., Dale, D. C. & Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J. Clin. Oncol.21(24), 4524\u20134531. https:\/\/doi.org\/10.1200\/JCO.2003.05.002 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"70187_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","volume":"100","author":"M Shayne","year":"2006","unstructured":"Shayne, M. et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res. Treat.100(3), 255\u2013262. https:\/\/doi.org\/10.1007\/s10549-006-9254-4 (2006).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"70187_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10549-011-1949-5","volume":"133","author":"D Weycker","year":"2012","unstructured":"Weycker, D. et al. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res. Treat.133(1), 301\u2013310. https:\/\/doi.org\/10.1007\/s10549-011-1949-5 (2012).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"70187_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman, G. H. et al. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer R Treat.139(3), 863\u2013872. https:\/\/doi.org\/10.1007\/s10549-013-2582-2 (2013).","journal-title":"Breast Cancer R Treat."},{"issue":"24","key":"70187_CR19","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1200\/JCO.2000.18.24.4028","volume":"18","author":"IJ Lewis","year":"2000","unstructured":"Lewis, I. J. et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J. Clin. Oncol.18(24), 4028\u20134037. https:\/\/doi.org\/10.1200\/JCO.2000.18.24.4028 (2000).","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"70187_CR20","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med.34(28), 3661\u20133679. https:\/\/doi.org\/10.1002\/sim.6607 (2015).","journal-title":"Stat. Med."},{"issue":"9491","key":"70187_CR21","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0140-6736(05)67110-3","volume":"366","author":"M Colleoni","year":"2005","unstructured":"Colleoni, M. et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet366(9491), 1108\u20131110. https:\/\/doi.org\/10.1016\/S0140-6736(05)67110-3 (2005).","journal-title":"Lancet"},{"key":"70187_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2407-11-131","volume":"11","author":"S Loibl","year":"2011","unstructured":"Loibl, S. et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer\u2014A pooled analysis. BMC Cancer11, 131. https:\/\/doi.org\/10.1186\/1471-2407-11-131 (2011).","journal-title":"BMC Cancer"},{"issue":"24","key":"70187_CR23","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/jnci\/92.24.1991","volume":"92","author":"S Paik","year":"2000","unstructured":"Paik, S. et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl. Cancer. Inst.92(24), 1991\u20131998. https:\/\/doi.org\/10.1093\/jnci\/92.24.1991 (2000).","journal-title":"J. Natl. Cancer. Inst."},{"issue":"1","key":"70187_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey, J. R. et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol.14(1), 72\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(12)70525-9 (2013).","journal-title":"Lancet Oncol."},{"issue":"14 Suppl 9","key":"70187_CR25","first-page":"16","volume":"20","author":"GH Lyman","year":"2006","unstructured":"Lyman, G. H. Chemotherapy dose intensity and quality cancer care. Oncology20(14 Suppl 9), 16\u201325 (2006).","journal-title":"Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70187-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:33:42Z","timestamp":1670322822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70187-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70187-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"13241"}}